• Citer

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

par Michiels, Stefan ;Pugliano, Lina ;Marguet, Sophie;Grun, D.;Barinoff, Jana;Cameron, D.;Cobleigh, Melody;Di Leo, Angelo ;Johnston, Stephen Rd D S.;Gasparini, Giampietro;Kaufman, Bella;Marty, Michel;Nekljudova, Valentina;Paluch-Shimon, Shani;Pénault-Llorca, Frederique;Slamon, Dennis;Vogel, Charles;Von Minckwitz, Gunter;Buyse, Marc;Piccart-Gebhart, Martine
Référence Annals of oncology, 27, 6, page (1029-1034), mdw132
Publication Publié, 2016-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
Auteur:	Michiels, Stefan; Pugliano, Lina; Marguet, Sophie; Grun, D.; Barinoff, Jana; Cameron, D.; Cobleigh, Melody; Di Leo, Angelo; Johnston, Stephen Rd D S.; Gasparini, Giampietro; Kaufman, Bella; Marty, Michel; Nekljudova, Valentina; Paluch-Shimon, Shani; Pénault-Llorca, Frederique; Slamon, Dennis; Vogel, Charles; Von Minckwitz, Gunter; Buyse, Marc; Piccart-Gebhart, Martine
Informations sur la publication:	Annals of oncology, 27, 6, page (1029-1034), mdw132
Statut de publication:	Publié, 2016-06
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	HER2
	Lapatinib
	Metastatic breast cancer
	Progression-free survival
	Surrogate
	Trastuzumab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdw132
	info:scp/84974806641